Intermittent chemotherapy can retain the therapeutic potential of anti-CD137 antibody during the late tumor-bearing state

Immunomodulating monoclonal antibodies (mAb) can evoke antitumor T-cell responses, which are attenuated by regulatory T cells (Treg) and myeloid-derived suppressor cells (MDSC). Treatment with cyclophosphamide (CP) and gemcitabine (GEM) can mitigate the immunosuppression by Treg and MDSC, respective...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cancer Sci
Main Authors: Tongu, Miki, Harashima, Nanae, Tamada, Koji, Chen, Lieping, Harada, Mamoru
Format: Artigo
Jezik:Inglês
Izdano: BlackWell Publishing Ltd 2015
Teme:
Original Articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4317772/
https://ncbi.nlm.nih.gov/pubmed/25363339
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12568
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki